life sciences

Anthropic says its life sciences team has run research partnerships with six organizations developing new medicines, and has started drug discovery programs of its own. Reported results include antibody designs, lead optimization data and an 89% cut in manufacturing document review time at Enveda.

Anthropic is setting up a physical biology lab in the San Francisco area where Claude will guide robots through drug experiments with minimal human involvement. The move follows the company's $400 million acquisition of Coefficient Bio and the addition of Novartis CEO Vas Narasimhan to its board.

Anthropic has launched the public beta of Claude Science, an AI workbench for scientific research that integrates NVIDIA's BioNeMo Agent Toolkit. The platform allows scientists to execute end-to-end research workflows using natural language commands to interact with digital agents.